Virological efficacy of 24-week fozivudine-based regimen in ART-naive patients from Tanzania and Côte d'Ivoire. - Wikidata - wikimedia - TriplyDB

Virological efficacy of 24-week fozivudine-based regimen in ART-naive patients from Tanzania and Côte d'Ivoire.

Virological efficacy of 24-week fozivudine-based regimen in ART-naive patients from Tanzania and Côte d'Ivoire.

http://www.wikidata.org/entity/Q37613239

about

Virological efficacy of 24-week fozivudine-based regimen in ART-naive patients from Tanzania and Côte d'Ivoire.

http://www.wikidata.org/entity/Q37613239

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Virological efficacy of 24-wee ...... om Tanzania and Côte d'Ivoire.

@en

Virological efficacy of 24-wee ...... om Tanzania and Côte d'Ivoire.

@nl

type

label

Virological efficacy of 24-wee ...... om Tanzania and Côte d'Ivoire.

@en

Virological efficacy of 24-wee ...... om Tanzania and Côte d'Ivoire.

@nl

prefLabel

Virological efficacy of 24-wee ...... om Tanzania and Côte d'Ivoire.

@en

Virological efficacy of 24-wee ...... om Tanzania and Côte d'Ivoire.

@nl

P1433

Q37613239-8435636E-4EB7-47F2-A5C4-8DE515168745

P1476

Q37613239-459DF621-03ED-4D14-8263-7AB818D75F95

P2093

Q37613239-581EAFD0-05B1-4820-AC43-CB5CADA18D75

Q37613239-64F96085-E82A-4BF1-BC98-8305DDDE3E9F

Q37613239-6A27A2EA-26B0-46B7-B2D5-A0747A5F97D0

Q37613239-74E7F839-1177-44A2-8D50-C13036C62D2E

Q37613239-8AC067AB-7533-4367-9DAF-1A274A88206A

Q37613239-8BA26B87-FA84-4EA7-9629-CA7E6F29D46B

Q37613239-8CDEAA4A-B8B4-42CC-8EF4-F8B9F485791E

Q37613239-DCEC8C3C-8F42-4C3E-85A1-2F64554F928F

Q37613239-DFAE0F2E-0F8D-42A3-80A0-BFACE724756C

Q37613239-F1AD6078-2334-4AA7-948F-4497FB3AEC4D

P2860

Q37613239-181343F7-5E0E-4F78-8651-BAE440A05006

Q37613239-3EF6EF72-38C2-47A1-8300-F071F39A55BC

Q37613239-53AB7103-EF4B-4DA7-9E87-45D087DC8E46

Q37613239-585D52F2-7110-4598-B8BE-423956D279E8

Q37613239-69E84B0A-1ABD-42BD-AB24-C478FFE2F7F7

Q37613239-6B3640FE-BC65-46FC-A9CD-B73EA76154A7

Q37613239-A67A8004-273B-4675-9A41-3A897E3AA70B

Q37613239-C9915657-5572-4499-BA02-B09EA4868561

Q37613239-E9EEE0BE-B435-4BB4-9689-6D9DCD38ADA4

Q37613239-FDC523AE-5F66-4128-9BF5-787324911D8E

P304

Q37613239-D7E61EAB-9C2F-44B5-96B6-980734BF7BA0

P31

Q37613239-E1692AA6-7BE3-4846-A0F1-C3504A2A2A50

P356

Q37613239-239D7551-C799-4FD9-933C-5B1761B091B4

P407

Q37613239-7202BE5B-2976-4DCB-94DB-479E434A7390

P433

Q37613239-87D7C662-63E8-4A87-8056-50F9987FC6B6

P478

Q37613239-D1D66596-A0F4-4FB9-8939-0C9AC75B798A

P50

Q37613239-236FDC4D-3466-455D-80C1-29A8621DE05F

Q37613239-619D80D3-F564-4D62-AF7B-7B37F9378BA0

Q37613239-BC058CFA-C998-40B1-AAE6-7F8D77D954AD

Q37613239-C63111DA-2348-48E7-BB86-E2C99E57CAD8

Q37613239-DD113AF4-168D-49CD-B37B-08C1A76B7851

Q37613239-E692840C-1B46-4811-9F67-BC9F08D96F67

P577

Q37613239-BFFFF3D0-2891-4DC2-93D1-ED0E2E138B83

P698

Q37613239-E4A2FB59-3CCF-4C46-A95D-626978F17F1D

P921

Q37613239-6F2C5FD6-E653-48C4-8CA3-E092515EEF1A

Q37613239-E9376BD3-C0AC-4058-8FE8-8D557F50A1A0

Q37613239-EC8062F2-A51D-4FB8-B789-73CAB0272834

P932

Q37613239-4AF16B9E-D8BE-44FF-9A78-CA8B36822F70

P356

QAD.0000000000001362

P1433

P1476

Virological efficacy of 24-wee ...... om Tanzania and Côte d'Ivoire.

@en

P2093

Arne Kroidl

http://www.w3.org/2001/XMLSchema#string

FATI-1 study team

http://www.w3.org/2001/XMLSchema#string

Frederic Ello

http://www.w3.org/2001/XMLSchema#string

Friedrich von Massow

http://www.w3.org/2001/XMLSchema#string

Jimson Mgaya

http://www.w3.org/2001/XMLSchema#string

Lucas Maganga

http://www.w3.org/2001/XMLSchema#string

Pierre-Marie Girard

http://www.w3.org/2001/XMLSchema#string

Ralph Zuhse

http://www.w3.org/2001/XMLSchema#string

Serge Eholie

http://www.w3.org/2001/XMLSchema#string

Tessa Lennemann

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire.

Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program.

Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

P304

501-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0000000000001362

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Xavier Anglaret

Michael Hoelscher

Christine Danel

P577

2016-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27941394

http://www.w3.org/2001/XMLSchema#string

P921

P932

5278894

http://www.w3.org/2001/XMLSchema#string